- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Aequus Pharmaceuticals announced the European Patent Office issued “an intention” to give the company a patent for AQS1301, Aequus’ once-weekly transdermal patch containing aripiprazole.
Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) announced the European Patent Office issued “an intention” to give the company a patent for AQS1301, Aequus’ once-weekly transdermal patch containing aripiprazole.
As quoted in the press release:
AQS1301 is in development for the treatment of certain psychiatric disorders and is intended to provide patients with a long-acting dosing alternative that is a comfortable, convenient and easy-to-use in an effort to promote medication adherence.
This is the eighth regional patent issued or granted for AQS1301, following US, Russia, Mexico, Japan, China, Canada and Australia.
“With this patent, Aequus has now achieved intellectual property that spans across all major pharmaceutical markets for its once-weekly transdermal aripiprazole program,” said Anne Stevens, COO and Director of Aequus Pharmaceuticals. “This patent grant coincides nicely with our accelerated business development efforts, as we look to further develop this program in collaboration with regional partners.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.